WALPAR NUTRITIONS Stock Price Today (NSE: WALPAR)
Fundamental Score
WALPAR NUTRITIONS Share Price Live NSE/BSE & Institutional Fundamental Analysis
WALPAR NUTRITIONS share price today is ₹39.60, up +0.00% on NSE/BSE as of 2 January 2026. WALPAR NUTRITIONS (WALPAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹37.19 (Cr). The 52-week high for WALPAR share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 15.96x, WALPAR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.09% and a debt-to-equity ratio of 0.48.
WALPAR NUTRITIONS Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
WALPAR NUTRITIONS Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
WALPAR NUTRITIONS Share Price: A Financial Stability Analysis
In the dynamic pharmaceutical sector, where innovation and regulatory compliance are paramount, a nuanced understanding of financial health is crucial. This analysis evaluates the financial stability of WALPAR NUTRITIONS based on available data. Examining the WALPAR NUTRITIONS share price of ₹39.6, along with its Price-to-Earnings (PE) ratio of 15.96 and Return on Capital Employed (ROCE) of 16.08%, offers valuable insights into its current position. This forms part of a larger 80-parameter fundamental audit, verified by Sweta Mishra.
The PE ratio of 15.96 suggests that the market is valuing WALPAR NUTRITIONS at approximately 15.96 times its earnings per share. To contextualize this, we need to consider sector benchmarks. Comparing it with peers like
Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd provides a relative valuation perspective. Ultimately, the market valuation of a company like Mankind Pharma is, in part, based on perceptions of management quality and future growth prospects. Differences in perceived management competence can significantly influence PE ratios across the sector.WALPAR NUTRITIONS' ROCE of 16.08% indicates the efficiency with which the company is generating profits from its capital employed. A strong ROCE, consistently maintained, can contribute significantly to building a competitive moat. This high return signifies effective utilization of resources, potentially allowing for reinvestment in research and development, expansion, or debt reduction. A robust ROCE relative to its sector peers could indicate a more sustainable competitive advantage, assuming the management team is equally adept at capital allocation over time.
In conclusion, while WALPAR NUTRITIONS' current financial metrics appear promising, further investigation into its growth trajectory, debt levels, and cash flow generation is essential for a comprehensive assessment. This observational analysis aims to provide a foundation for informed decision-making, acknowledging that a complete picture requires a broader scope, especially regarding comparison to larger pharma companies.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
WALPAR NUTRITIONS Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WALPAR across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Return on Equity (15.09%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (16.08%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 15.96 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Interest Coverage (12.64x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (68.61%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Negative Free Cash Flow (₹-5.97 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
WALPAR NUTRITIONS Financial Statements
Comprehensive financial data for WALPAR NUTRITIONS including income statement, balance sheet and cash flow
About WALPAR (WALPAR NUTRITIONS)
WALPAR NUTRITIONS (WALPAR) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹37.19 (Cr). WALPAR NUTRITIONS has delivered a Return on Equity (ROE) of 15.09% and a ROCE of 16.08%. The debt-to-equity ratio stands at 0.48, reflecting the company's capital structure. Investors tracking WALPAR share price can monitor key metrics including P/E ratio, promoter holding of 68.61%, and quarterly earnings growth.
Company Details
WALPAR Share Price: Frequently Asked Questions
What is the current share price of WALPAR NUTRITIONS (WALPAR)?
As of 02 Jan 2026, 04:16 pm IST, WALPAR NUTRITIONS share price is ₹39.60. The WALPAR stock has a market capitalisation of ₹37.19 (Cr) on NSE/BSE.
Is WALPAR share price Overvalued or Undervalued?
WALPAR share price is currently trading at a P/E ratio of 15.96x, compared to the industry average of 31.77x. Based on this relative valuation, the WALPAR NUTRITIONS stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of WALPAR share price?
The 52-week high of WALPAR share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the WALPAR NUTRITIONS share price?
Key factors influencing WALPAR share price include quarterly earnings growth (Sales Growth: 12.17%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is WALPAR NUTRITIONS a good stock for long-term investment?
WALPAR NUTRITIONS shows a 5-year Profit Growth of N/A% and an ROE of 15.09%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.48 before investing in WALPAR shares.
How does WALPAR NUTRITIONS compare with its industry peers?
WALPAR NUTRITIONS competes with major peers in the Pharmaceuticals. Investors should compare WALPAR share price P/E of 15.96x and ROE of 15.09% against the industry averages to determine competitive standing.
What is the P/E ratio of WALPAR and what does it mean?
WALPAR share price has a P/E ratio of 15.96x compared to the industry average of 31.77x. Investors pay ₹16 for every ₹1 of annual earnings.
How is WALPAR performing according to Bull Run's analysis?
WALPAR has a Bull Run fundamental score of 34.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does WALPAR belong to?
WALPAR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting WALPAR NUTRITIONS share price.
What is Return on Equity (ROE) and why is it important for WALPAR?
WALPAR has an ROE of 15.09%, which indicates excellent management efficiency. ROE measures how efficiently WALPAR NUTRITIONS generates profits from shareholders capital.
How is WALPAR debt-to-equity ratio and what does it indicate?
WALPAR has a debt-to-equity ratio of 0.48, which indicates moderate leverage that should be monitored.
What is WALPAR dividend yield and is it a good dividend stock?
WALPAR offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in WALPAR NUTRITIONS shares.
How has WALPAR share price grown over the past 5 years?
WALPAR has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in WALPAR and why does it matter?
Promoters hold 68.61% of WALPAR shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in WALPAR NUTRITIONS.
What is WALPAR market capitalisation category?
WALPAR has a market capitalisation of ₹37 crores, placing it in the Small-cap category.
How volatile is WALPAR stock?
WALPAR has a beta of N/A. A beta > 1 suggests the WALPAR NUTRITIONS stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is WALPAR operating profit margin trend?
WALPAR has a 5-year average Operating Profit Margin (OPM) of 7.63%, indicating the company's operational efficiency.
How is WALPAR quarterly performance?
Recent quarterly performance shows WALPAR NUTRITIONS YoY Sales Growth of 12.17% and YoY Profit Growth of 0.00%.
What is the institutional holding pattern in WALPAR?
WALPAR has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the WALPAR NUTRITIONS stock.